Aspartic Pharma is a globally focused clinical-stage biotechnology company dedicated to developing novel therapies for cancer, hepatitis B virus, and age-related diseases. The company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. Aspiration Pharma has developed new products including eight drug candidates, including novel high-potency Bcl-2/Bcl-XL inhibitors, drug candidates targeting IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 phase I/II clinical trials to evaluate eight products in the US, Australia, and China to develop potential therapies as single drugs or combinations.